actym therapeutics word
actym therapeutics logo

Our Science

Actym Therapeutics, based in Berkeley, CA, is a privately held biotechnology company focused on the discovery and development of novel immunotherapies to treat cancer. The company has developed an attenuated, microbial-based, technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident antigen-presenting cells. Many of these payload targets are intractable using conventional approaches due to systemic toxicities after IV dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. The STACT platform is protected by a robust patent estate which includes an issued US patent that covers the core technology through at least August, 2039.

 

The company’s lead program, ACTM-838, a STACT strain that encodes engineered IL-15 (IL-15plex) and STING (eSTING), is rapidly advancing to the clinic. In preclinical studies, the IL-15plex + eSTING payload combination delivered by STACT resulted in primary human and mouse M2 macrophage production of type I interferon, and repolarization into a novel hybrid M1/M2 phenotype capable of tumor cell phagocytosis and priming of CD8+ T-cells. Complete tumor responses were observed in metastatic, checkpoint refractory tumors (IV dosing), that were entirely dependent on CD8+ T-cells. In primates, STACT was well tolerated, rapidly cleared, and elicited minimal cytokine responses after IV dosing. In February of 2022, Actym signed a global manufacturing contract with Wacker Biotech, a leading CDMO for production of live bacterial products, for ACTM-838 clinical supply.

 

Actym is also developing a broad pipeline of additional therapeutic candidates intended to treat checkpoint refractory histologies across the solid tumor spectrum through DNA, mRNA, and protein delivery.

 

Actym is backed by top tier investors including Boehringer-Ingelheim Venture Fund, Panacea Venture Healthcare, Illumina Ventures, Korea Investment Partners, and JLO Ventures.